Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche and Warp Drive Bio ally on antibiotic development

Roche and Warp Drive Bio ally on antibiotic development

18th October 2017

Roche has announced a new collaboration with Warp Drive Bio that will see the companies working together to create new antibiotic therapies.

Under the collaboration, Warp Drive will utilise its proprietary Genome Mining Platform to advance multiple novel classes of antibiotics that could offer activity against clinically important drug-resistant Gram-negative pathogens.

With this platform, the partners will be able to gain access to natural product drugs that have not been analysed previously, due to historical technology limitations, with more than 100 novel classes of potential antibiotics set to be assessed.

Roche will receive an option for an exclusive worldwide license to develop and commercialise certain antibiotic classes that emerge from the collaboration, with Warp Drive to retain worldwide rights to all other novel antibiotics.

Dr Laurence Reid, chief executive officer of Warp Drive Bio, said: "We are committed to bringing urgently needed novel antibiotic medicines to patients, and we are delighted to be collaborating with Roche in that goal."

There are currently ten classes of natural antibiotics that have been approved for patient use, plus five classes of synthetic antibiotics. The last antibiotic from a novel natural class approved in the US was discovered more than 30 years ago.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.